Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 4/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL4286270 | 0.96 | MAT2A (0.40) | MAT2AMAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL4286272 | 0.90 | MAT2A (0.38) | MAT2AMAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL4286319 | 0.83 | MAPK14 (0.49) | MAT2AMAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1065428 | 0.82 | MAT2A (0.42) | MAT2AMAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL4288511 | 0.79 | MAT2A (0.41) | MAT2AMAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL4290162 | 0.79 | MAPK14 (0.49) | MAT2AMAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL4290530 | 0.79 | MAPK14 (0.46) | MAT2AMAPK14MAPK11MAPK13MAPK12 | |
| Formic Acid SCHEMBL4290417 | 0.78 | MAT2A (0.38) | MAT2AMAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1063553 | 0.70 | FGFR1 (0.40) | MAT2AMAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1064417 | 0.68 | SCN9A (0.37) | MAT2AMAPK14MAPK11MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | claimed |
| US-20060211727-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2006-09-21 | — | — | US | claimed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-20060211727-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239897-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, MAPK1 | MAT2A 4329/4885MAPK14 32/4885MAPK11 66/4885 |
| US-20060211727-A1 | Novel compounds | MAPKAPK2, CREBBP, MAPK1 | MAT2A 4329/4885MAPK14 32/4885MAPK11 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.